Cytosurge

Cytosurge develops innovative research solutions using its proprietary FluidFM® technology for precise single-cell manipulation thereby fostering advancements in understanding cellular processes such as the ones that drive cancer. With the FluidFM OMNIUM platform, single-cell extracts, or “biopsies” can be taken from living cells, enabling live-sequencing and temporal transcriptomics analysis. Additionally, the CellEDIT Service provides high-quality genetically engineered cell lines through intra-nuclear injections of CRISPR RNPs. Cytosurge's vision is to unlock novel cures by translating next-generation genetic designs into living cells, thereby enabling longer and healthier lives through precision gene engineering. The Company aims to implement advanced genetically engineered cell lines that bring next-generation therapies to fruition, bridging the gap between genetic design tools and manufacturing, and empowering genetic engineers to realize their visionary concepts.#FluidFM #AFM #mRNA #scRNAseq #LiveSeq #Transcriptomics #Genomics #CellEDIT #CRISPR #GeneEditing #GeneEngineering #CRISPRGeneEditing #GeneticEngineering #CellLineDevelopment #DNAmodifications